Feb. 2, 2021 /PRNewswire/
-- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic
biotechnology company active in the Clean Health and Beauty markets
through its consumer brands and a top supplier of sustainable and
natural ingredients, today announced breakthrough results in an
early clinical study of Amyris's clean topical formulation of
fermentation-based ingredients for the treatment of acne.
In the study which was conducted by Princeton Consumer Research
Corp (PCR) - the global specialist in cosmetic testing and clinical
trials for world-wide claims substantiation - Amyris's acne
formulation, consisting of two of its clean, fermentation-based
ingredients, demonstrated superior efficacy compared to 10 other
standard acne treatments currently available in the United States. Efficacy was measured in
terms of magnitude of acne reduction and the time it takes for such
The global acne treatment market was valued at approximately
$11 billion in 2019 according to
Allied Market Research. North
America accounted for the largest share of revenue in 2019.
With China as the biggest market,
Asia-Pacific is expected to
register the highest growth globally over the next five years. Acne
or acne vulgaris is one of the most common skin conditions,
affecting up to 50 million Americans annually, including
approximately 85 percent of people between the ages of 12 and 24.
In addition, due to the wearing of face masks to protect against
COVID-19 infection, the incidence of "maskne"-related acne has been
rising. Maskne is a skin condition caused by wearing a face mask or
other covering, symptoms of which can include acne around the nose,
cheeks, mouth and chin.
Enabled by its proprietary Lab-to-Market science platform,
Amyris has a track record of developing and producing naturally
sourced ingredients. Most current acne treatments are formulated
with chemicals. Amyris' unique formulation is the latest discovery
of a clean formulation for the beauty market which contains natural
and sustainably sourced ingredients that are highly effective while
nourishing the skin and doing no harm to the planet.
"We are very pleased with the early clinical results
demonstrating the power of our science to address the most common
skincare issues," said John Melo,
President and Chief Executive Officer of Amyris. "We are working on
finalizing our proprietary acne formulation, advancing intellectual
property protection, and preparing for an accelerated consumer
launch. We are very excited about the potential of becoming a
market leader in topical acne treatments with our clean, natural,
and sustainably-sourced ingredients. This formulation will further
expand Amyris's clean beauty brand leadership combining our science
with the best performing products sold direct to the consumer."
Amyris (Nasdaq: AMRS) is a science and
technology leader in the research, development and production of
sustainable ingredients for the Clean Health & Beauty and
Flavors & Fragrances markets. Amyris uses an impressive array
of exclusive technologies, including state-of-the-art machine
learning, robotics and artificial intelligence. Our ingredients are
included in over 3,000 products from the world's top brands,
reaching more than 200 million consumers. Amyris is proud to own
three consumer brands - all built around its No Compromise® promise
of clean ingredients: Biossance® clean beauty
skincare, Pipette® clean baby skincare and
Purecane™, a zero-calorie sweetener naturally derived from
sugarcane. For more information, please visit www.amyris.com.
This release contains
forward-looking statements, and any statements other than
statements of historical fact could be deemed to be forward-looking
statements. These forward-looking statements include, among other
things, statements regarding Amyris's plans to finalize its
proprietary acne formulation, advance intellectual property
protection, and prepare for an accelerated consumer launch; and
Amyris's expectation of becoming a market leader in topical acne
treatments and expanding its presence in the clean beauty space.
These statements are based on management's current expectations and
actual results and future events may differ materially due to risks
and uncertainties, including risks related to delays or failures in
development, regulatory approval, production and commercialization
of products; risks related to Amyris's reliance on third parties
(including in the supply chain); Amyris's liquidity and ability to
fund operating and capital expenses; and other risks detailed from
time to time in filings Amyris makes with the Securities and
Exchange Commission, including Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
Amyris disclaims any obligation to update information contained in
these forward-looking statements, whether as a result of new
information, future events, or otherwise.
Amyris, the Amyris logo, No Compromise, Biossance, Pipette, and
Purecane are trademarks or registered trademarks of Amyris, Inc. in
the U.S. and/or other countries.
View original content to download
SOURCE Amyris, Inc.